Article
Oxycodone/naloxone versus Tapentadol in real-world chronic non-cancer pain management: a prospective controlled and pharmacogenetic study
2024-01-31
Abstract excerpt
<h4>Background: </h4> and purpose: Tapentadol (TAP) and oxycodone/naloxone (OXN) are available formulations that potentially offer improved gastrointestinal tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. The aim is to analyse their benefit/risk profiles and the influence of pharmacogenetic markers in daily pain practice. Experimental approach: A prospective, controlled s...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 975ea959-e1b3-52ed-94c5-a5a962bc5751
- DOI
- 10.22541/au.170666297.73406141/v1
